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Condensation: Higher maximum doses of oxytocin should be used cautiously in VBAC 
trials, and considering an upper limit of 20 mu/min seems reasonable. 
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Title: Higher maximum doses of oxytocin are associated with an unacceptably high risk 
for uterine rupture in patients attempting VBAC 
Authors: Alison G. Cahill, M.D., Brian M. Waterman, M.P.H., David M. Stamilio, M.D., 
M.S.C.E., Anthony O. Odibo, M.D., M.S.C.E, Jenifer E. Allsworth, Ph.D., Bradley 
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Objective: To more precisely estimate the effect of maximum oxytocin dose on uterine 
rupture risk in patients attempting VBAC by considering timing and duration of therapy.  
Study design: A nested case-control study was conducted within a multicenter, 
retrospective cohort study of over 25,000 women with at least one prior cesarean 
delivery, comparing cases of uterine rupture to controls (no rupture) while attempting 
VBAC. Time-to-event analyses were performed to examine the effect of maximum 
oxytocin dose on the risk of uterine rupture considering therapy duration, while adjusting 
for confounders. 
Results: Within the nested case-control study of 804 patients, 272 were exposed to 
oxytocin: 62 cases of uterine rupture and 210 controls. Maximum oxytocin ranges above 
20mu/min increased the risk of uterine rupture 4-fold or greater (21-30mu/min: HR=3.92, 
95%CI 1.06-14.52; 31-40mu/min: HR=4.57, 95%CI 1.00-20.82). 
Conclusion: These findings support a maximum oxytocin dose of 20mu/min in VBAC 
trials to avoid an unacceptably high risk of uterine rupture. 
 




 While attempts at vaginal birth after cesarean (VBAC) have become a common 
part of obstetric practice, largely due to recently published, well-designed studies 1, 2 
quantifying the relatively low rates of maternal and neonatal risks associated with VBAC, 
practitioners are facing the complex reality of the intrapartum management of these 
VBAC trials with little evidence for guidance. As the number of women with a prior 
cesarean rises3, so does the number of labor inductions, creating a paradox between the 
large number of patients attempting VBAC who require oxytocin for labor induction or 
augmentation, and the small amount of published data on oxytocin use in VBAC trials. 
This frequently encountered clinical scenario leaves clinicians to extrapolate data and 
guidelines from management in patients without a uterine scar to those attempting 
VBAC. 
Any assessment of the safety of oxytocin use in VBAC trials must consider both 
dose and time. While some studies have described a small, increased risk for uterine 
rupture associated with oxytocin use2, others have reported no association between 
oxytocin and the risk for uterine rupture4. Most importantly, no studies have addressed 
the role that time may play in risk of uterine rupture imparted by oxytocin use. We sought 
to more precisely estimate the effect of maximum oxytocin dose on the risk of uterine 
rupture in patients attempting VBAC by considering timing and duration of oxytocin 
dose. 
 
Materials and Methods: 
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 From 1995 to 2000, a 17-center, retrospective cohort study was conducted in the 
northeastern United States, enrolling all patients with at least one prior cesarean delivery. 
Institutional Review Board approval was obtained at all sites. This study was conducted 
to assess the risks of VBAC-associated maternal morbidities, and to ascertain if uterine 
rupture could be predicted. Nested within this large cohort, a case-control study was 
designed, defining cases as patients experiencing a symptomatic uterine rupture, and then 
randomly selecting control patients from those who underwent a VBAC trial but did not 
experience a uterine rupture, in a ratio of 5:1, matched on hospital site. Details of the 
cohort study have been described elsewhere1, but a brief description follows. 
 Participants were identified by International Classification of Disease 9th Revision 
(ICD-9) code, using the term “previous cesarean delivery, delivered”. The sensitivity of 
this ICD code-based search was validated in pilot studies prior to study initiation. Trained 
research nurses extracted charts using closed-ended data extraction forms, and 3% of 
charts were re-extracted for quality assurance. Patients were excluded if the type of scar 
from their prior cesarean was either unknown or non-low-transverse. Extensive data was 
collected on maternal demographics, medical and obstetric history, antenatal and 
peripartum events, and maternal outcomes. During re-abstraction for the patients in the 
case-control study, detailed patient-level information was collected on labor progress in 
15 minute intervals, including exams, medications, and dosing. Thus, labor curves can be 
effectively reconstructed for all of the patients in the case-control study. 
 The definition of symptomatic uterine rupture (case) was specified a priori, and 
equivocal cases were reviewed and status determined by the primary investigator. To 
distinguish these cases from less clinically relevant incidental findings of asymptomatic 
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uterine dehiscence and uterine “windows”, cases of uterine rupture required a full-
thickness scar separation and at least one of the following clinical markers: 
hemoperitoneum, signs of maternal hemorrhage (including systolic blood pressure <70, 
diastolic blood pressure <40, or heart rate >120), or nonreassuring fetal heart rate pattern 
immediately preceding surgery. 
 For this analysis, we studied all patients exposed to oxytocin in the nested case-
control study, comparing patients who experienced a uterine rupture to those who did not. 
Cases and controls were compared on baseline characteristics, using χ2 analysis for 
dichotomous variables and Student’s t-test or Mann-Whitney U test, as appropriate, for 
continuous variables. Additionally, a sensitivity analysis of sociodemographics and 
oxytocin parameters was performed, comparing the controls used for this analysis to the 
group of patients who did not experience a uterine rupture in the larger cohort to ensure 
that the controls chosen at random were representative (data available upon request).  
For the time-to-event analyses, patients were classified as having the event of 
interest (uterine rupture) or were censored (delivered). We considered three clinically 
relevant time periods by defining time-to-event three distinct ways. The first was duration 
of labor, where time zero was specified as time of labor floor admission. The second was 
duration of oxytocin exposure, where time zero was specified as time of initiation of 
oxytocin therapy for labor induction or augmentation, and the third was duration of 
maximum oxytocin exposure, where time zero was specified as initiation of maximum 
oxytocin dose. 
Maximum oxytocin dose was categorized into clinically relevant ranges (1-5, 6-
20, 21-30, 31-40 mu/min), specifying the range of 1-5mu/min as the reference. For all 
 7 
time-to-event analyses, Kaplan-Meier plots were used for graphical illustration of the risk 
of uterine rupture over time by stratum of maximum oxytocin range. Dummy variables 
were created with the 4 dose ranges of maximum oxytocin and the lowest range was 
designated as the reference. Using each of the three periods of observation, Cox 
proportional hazard regression was used to model the effect of maximum oxytocin dose 
on the risk for uterine rupture, adjusting for relevant confounding effects identified in the 
unadjusted analysis. Data was nearly complete for all covariates. Imputed values were not 
used in the regression analysis for missing data since they represented less than 2% of the 
data for any given variable. The proportional hazards assumption was tested using the 
global test of Grambsch and Therneau5. All statistical analysis was completed with 
STATA software package (v 8, Special Edition; Stata Corporation, College Station, TX). 
  
Results:  
Within a cohort of 25,005 patients with a history of at least one prior cesarean 
delivery, 13,706 attempted VBAC. Of those who attempted VBAC, 134 experienced a 
uterine rupture and were defined as cases. At random, 670 of the 13,706 patients who 
attempted VBAC but did not experience a uterine rupture were selected as controls. For 
this analysis of all 272 patients in the nested case-control study exposed to oxytocin, 62 
cases of uterine rupture were compared to 210 controls. The two groups were similar in 
age, gravidity, gestational age at delivery, care site, comorbidities, and tobacco and 
alcohol use. However, patients who experienced uterine rupture were less likely to have 
had a prior vaginal delivery (15.0% vs. 32.2%, p=0.009), had a higher rate of induction as 
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compared to augmentation (75.0 % vs. 58.6%, p=0.021), and were more likely to have 
had more than one prior cesarean delivery (18.3% vs. 9.1%, p=0.047) (Table 1). 
 The maximum dose of oxytocin exposure was divided into 4 ranges (1-5, 6-20, 
21-30, and 31-40mu/min). Using the lowest dose range as reference, a Kaplan-Meier plot 
displayed divergent survival curves, with the greater divergence in uterine rupture risk 
seen as duration of exposure becomes longer (Figure). 
 When Cox proportional hazard models were built to estimate the effect of 
maximum oxytocin dose on risk of uterine rupture, the results varied depending on the 
time period used for the time-to-event analysis. Table 2 presents the Cox proportional 
hazard model of the effect of the designated dose ranges of maximum oxytocin on the 
risk for uterine rupture, when time of observation was defined as time from initiation of 
maximum oxytocin dose to event or censor. The final Cox model adjusted for three 
relevant covariates: history of a prior vaginal delivery, induction (vs. augmented) labor, 
and number of prior hysterotomies. Neither number of prior cesareans nor cervical 
dilation (<4 vs ≥ 4 centimeters dilated at the time of oxytocin initiation) remained 
significant in the final model. We found a dose-response relationship between increased 
maximum oxytocin dose exposure and increased risk of uterine rupture. The dose range 
6-20mu/min had a slightly greater than 3-fold increase risk of uterine rupture (HR=3.34, 
95%CI 1.01-10.98). And at ranges of maximum oxytocin doses over 20mu/min, the 
increase in risk of uterine rupture was 4-fold or greater (21-30mu/min: HR=3.92, 95%CI 
1.06-14.52; 31-40mu/min: HR=4.57, 95%CI 1.00-20.82). These adjusted analyses 
estimate the attributable risk of uterine rupture to be 2.9% and 3.6% for maximum 
oxytocin dose ranges above 20 and 30 milliunits per minute, respectively 
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 Conversely, when defining the observation period as duration of labor or duration 
of any oxytocin therapy (as opposed to duration of maximum oxytocin dose) for the Cox 
model, there appeared to be no association between maximum oxytocin dose and uterine 
rupture risk. Even at the highest range of maximum oxytocin dose (31-40mu/min), 
neither defining time as duration of labor (HR=1.62, 95%CI 0.40-6.59) nor defining time 
as duration of oxytocin exposure (HR=0.62, 95%CI 0.12-3.01) revealed a significant 
increased risk association. 
 
Comment: 
 When the timing and duration of oxytocin dose is considered, increasing ranges of 
maximum oxytocin dose are associated with a progressively increasing risk of uterine 
rupture in patients attempting VBAC. This association with uterine rupture risk, 
estimated by time-to-event analysis, is greater in magnitude than that previously 
described by multivariable models that did not consider time or duration of therapy2, 4, 6-9. 
This finding warrants setting limits on oxytocin use in VBAC trials. 
 In a 2001, Goetzl et al 4 published a small, case-control study of patients 
undergoing a VBAC trial, and reported no difference in oxytocin dose and duration 
between the 24 patients who experienced a uterine rupture and the 96 who did not. 
Though they reported no difference in oxytocin duration or oxytocin dose between cases 
of uterine rupture and controls, they were unable to adjust for relevant confounding 
variables, unable to examine a wide range of maximum doses since the study was 
performed at a single center, and could not fully explore the effect of therapy duration 
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because they did not use time-based analyses. Additionally, the sample size restricted the 
study’s power to identify a difference in oxytocin exposure. 
 Since then, two studies have identified that there is in fact a risk association 
between oxytocin and uterine rupture. Landon et al 2 performed a large, prospective 
cohort study of VBAC candidates, and found that augmentation and induction with 
oxytocin were associated with an increased risk of uterine rupture (adjusted OR 2.42, 
95% CI 1.49-3.93, and adjusted OR 3.01, 95% CI 1.66-5.46, respectively). Cahill et al10, 
in a secondary analysis of a large retrospective cohort, reported a dose-response 
relationship between maximum oxytocin dose and risk of uterine rupture, comparing 
VBAC candidates who were exposed to oxytocin to those who were not. However, 
neither study addressed the clinically and physiologically significant role of time or 
therapy duration, and thus may not have most accurately estimated the true risk 
association between oxytocin, or more specifically maximum oxytocin dose, and uterine 
rupture. 
 In this study, we considered the possibility that the association of maximum 
oxytocin dose exposure and the risk of uterine rupture might be most precisely estimated 
using time-to-event analysis. The nested case-control design of our study afforded several 
advantages. It allowed us to examine the risk of a rare outcome with sufficient power to 
adjust for several relevant confounding variables without over-fitting our multivariable 
models. Since the study was nested within a large, retrospective, multicenter cohort, it 
enabled us to choose controls from the same population as the cases, reducing the chance 
for selection bias. 
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 To assure that the controls were truly a random sample from the entire cohort that 
did not experience a uterine rupture (non-event population), we performed a sensitivity 
analysis of oxytocin parameters. There was no significant difference between the controls 
used for this analysis and the larger sample from which they were drawn, specifically 
with regard to oxytocin exposure and demographic variables, further supporting the lack 
of significant selection bias. 
 Time-to-event analysis allowed us to consider three clinically relevant time 
frames in the assessment of maximum oxytocin dose and risk of uterine rupture. When 
event-time was defined as duration of labor or duration of oxytocin exposure, while 
clinically appropriate, these definitions of time of exposure likely incorporate left 
censoring and introduced selection bias. That is, due to variation in labor at time of 
presentation and variability in oxytocin initiation and management, these definitions 
likely incorporated patients who were at risk during time not observed, which could have 
biased the results in either direction. By defining time at risk as time from initiation of 
maximum oxytocin dose to uterine rupture or delivery, we were able to more precisely 
estimate the risk association since all of the time at risk was observed. 
 Despite these efforts to minimize selection bias, some may still exist. However, it 
is unlikely to have occurred with regard to selection of the cases, since the definition of 
uterine rupture was defined strictly and a priori, and equivocal cases were reviewed for 
classification. If significant bias occurred in random selection of the controls, the 
nonsignificant trends in the sensitivity analysis support an over-sampling in the higher 
ranges of maximum oxytocin which, if anything, would have falsely diminished the 
observed risk estimates in relation to the true risk of uterine rupture. Finally, despite the 
 12 
large sample size, the outcome is a rare event which limits the precision of the risk 
estimates.  
 Given the results of our analyses, the magnitude of increased risk for uterine 
rupture at higher maximum dose ranges of oxytocin is concerning. As compared to 
previous risk estimates that suggested an approximately 1% attributable risk of uterine 
rupture at the highest range of maximum oxytocin doses, these results estimate the 
attributable risk to be 2.9% and 3.6% for maximum oxytocin dose ranges above 20 and 
30 milliunits per minute, respectively. While an increase in uterine rupture risk of 1% 
seems clinically acceptable, 2.9% and 3.6% are less so. From this data, we believe that 
higher maximum doses of oxytocin should be used cautiously in VBAC trials, and that an 
upper limit of 20 mu/min seems reasonable. 
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Title: Kaplan-Meier plot of risk for uterine rupture with increasing ranges of maximum 
oxytocin exposure 
Key: Maximum oxytocin ranges: 
1 - (6-20 mu/min) 
2 - (21-30 mu/min) 
3 - (31-40 mu/min) 
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Table 1: Baseline characteristics of cases and controls exposed to oxytocin 
Variable Cases (N=62) Controls (N=210) p 
Maternal age (years) 31.3 ± 5.14 30.3 ± 5.40 0.186 
Gravidity (mean) 3.21 ± 1.59 3.27 ± 1.51 0.785 
Gestational age @ delivery (wk) 38.6 ± 4.90 38.7 ± 3.11 0.869 
Delivery prior to 34 weeks (%) 1.7 3.4 0.496 
Delivery after 41 weeks (%) 15.0 21.6 0.259 
Birth weight (grams) 3442 ± 701.3 3454 ± 743.5 0.919 
> 1 prior cesarean (%) 18.3 9.1 0.047 
Prior vaginal delivery (%) 15.0 32.2 0.009 
Prior cesarean for cephalopelvic 
disproportion (%) 
10.0 10.6 0.898 
Induction of labor (%) 75.0 58.6 0.021 
Twin gestation (%) 1.7 0.5 0.344 
Asthma (%) 8.1 10.9 0.511 
Chronic hypertension (%) 3.2 6.2 0.365 
Any gestational hypertensive 
disease (%) 
11.7 6.7 0.210 
Diabetes (%) 3.2 2.9 0.885 
Alcohol use (%) 5.0 6.0 0.783 
Tobacco use (%) 11.7 17.2 0.307 
University hospital (%) 68.3 67.8 0.936 
Obstetric residency (%) 25.0 36.0 0.110 
 16 
Table 2: Cox proportional hazard model of effect of maximum oxytocin 
dose on risk of uterine rupture 
Maximum oxytocin 
dose (mu/min) 
Hazard Ratio 95% CI p 
1-5 (n=89) ref - - - - 
6-20 (n=119) 3.34 1.01-10.98 0.047 
21-30 (n=48) 3.92 1.06-14.52 0.040 
31-40 (n=16) 4.57 1.00-20.82 0.050 
*Significant covariates in model: history of prior vaginal delivery, induction or 
spontaneous labor, number of prior hysterotomies 
 
